OBJECTIVE: To determine whether corrodible materials may be safely used as biodegradable cardiovascular implants. DESIGN: Corrodible iron stents (> 99.8% iron) were produced from pure iron and laser cut with a stent design similar to a commercially available permanent stent (PUVA-AS16). A total of 16 NOR-I stents were implanted into the native descending aorta of 16 New Zealand white rabbits (mean luminal diameter at the implantation site 3.4 mm, balloon diameter to vessel diameter ratio 1.13). RESULTS: No thromboembolic complications and no adverse events occurred during the follow up of 6-18 months. All stents were patent at repeat angiography after 6 (n = 9), 12 (n = 5), and 18 months (n = 2) with no significant neointimal proliferation, no pronounced inflammatory response, and no systemic toxicity. CONCLUSIONS: This initial in vivo experience suggests that degradable iron stents can be safely implanted without significant obstruction of the stented vessel caused by inflammation, neointimal proliferation, or thrombotic events.
OBJECTIVE: To determine whether corrodible materials may be safely used as biodegradable cardiovascular implants. DESIGN: Corrodible iron stents (> 99.8% iron) were produced from pure iron and laser cut with a stent design similar to a commercially available permanent stent (PUVA-AS16). A total of 16 NOR-I stents were implanted into the native descending aorta of 16 New Zealand white rabbits (mean luminal diameter at the implantation site 3.4 mm, balloon diameter to vessel diameter ratio 1.13). RESULTS: No thromboembolic complications and no adverse events occurred during the follow up of 6-18 months. All stents were patent at repeat angiography after 6 (n = 9), 12 (n = 5), and 18 months (n = 2) with no significant neointimal proliferation, no pronounced inflammatory response, and no systemic toxicity. CONCLUSIONS: This initial in vivo experience suggests that degradable iron stents can be safely implanted without significant obstruction of the stented vessel caused by inflammation, neointimal proliferation, or thrombotic events.
Authors: H Tamai; K Igaki; E Kyo; K Kosuga; A Kawashima; S Matsui; H Komori; T Tsuji; S Motohara; H Uehata Journal: Circulation Date: 2000-07-25 Impact factor: 29.690
Authors: L N Benson; F Hamilton; H Dasmahapatra; M Rabinowitch; J C Coles; R M Freedom Journal: J Am Coll Cardiol Date: 1991-11-01 Impact factor: 24.094
Authors: Hu Tao; Suk-Won Hwang; Benedetto Marelli; Bo An; Jodie E Moreau; Miaomiao Yang; Mark A Brenckle; Stanley Kim; David L Kaplan; John A Rogers; Fiorenzo G Omenetto Journal: Proc Natl Acad Sci U S A Date: 2014-11-24 Impact factor: 11.205
Authors: Toktam Ghassemi; Azadeh Shahroodi; Mohammad H Ebrahimzadeh; Alireza Mousavian; Jebraeel Movaffagh; Ali Moradi Journal: Arch Bone Jt Surg Date: 2018-03